latest news releases from the newsroom
Sigma Opens New Subsidiary in Lulea
STOCKHOLM, Sweden, Feb. 6, 2002 (PRIMEZONE) -- Sigma has established a new subsidiary in Lulea - Sigma InfoSolutions. The company was created through a division of Sigma iSoft. The reason for creating the new company was to streamline operations and facilitate ongoing expansion.
Sectra Announces Cooperation Agreement with MD OnLine
LINKOPING, Sweden, Feb. 6, 2002 (PRIMEZONE) -- The Swedish medical technology and IT company Sectra has signed an agreement with MD OnLine (MDOL), an industry leader in computer-aided diagnostic support software, for the integration of MDOL's ImageMatch technology in Sectra's digital radiology systems.
Karo Bio and GPC Biotech Successfully Develop Ten Assays for Novel Anibacterial Targets
MUNICH, Germany, Feb. 6, 2002 (PRIMEZONE) -- Karo Bio USA, Inc., a wholly owned subsidiary of Karo Bio AB, and GPC Biotech AG (Frankfurt Stock Exchange: GPC) today announced that their technology collaboration has been successfully concluded in a period of only 15 months with the development of 10 BioKey(r) molecular probe assays for selected novel genomics-derived antibacterial targets proprietary to GPC Biotech. GPC Biotech is using these BioKey(r) molecular probe assays to develop high-throughput drug discovery screens (HTS) and has already successfully concluded a HTS for one assay. Karo Bio has received undisclosed milestone payments for the completion of these BioKey(r) molecular probe assays.
Picovir -- pleconaril -- to be Reviewed by FDA Antiviral Drugs Advisory Committee on March 19, 2002
EXTON, Pa. and BRIDGEWATER, N.J., Feb. 6, 2002 -- ViroPharma Incorporated (Nasdaq:VPHM) and Aventis Pharmaceuticals, the U.S. pharmaceutical company of Aventis Pharma AG, today announced that the new drug application for Picovir (pleconaril), an investigational product being developed for the treatment of viral respiratory infection (VRI, or the common cold) in adults, is scheduled to be reviewed by the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) on March 19, 2002.